For example, the use of Oxaliplatin (Folfox) in combination with anti-PD-1 antibodies in a murine model of CRC and in samples of patients reduced the number of tumors, which does not happen if these compounds are used individually [132]. Here, PDCD1 is linked to colorectal carcinoma.